CompletedPhase 3

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

Dedicated Clinical Research

Sun City, Arizona, United States

+22 additional locations

Save this trial

Dedicated Clinical ResearchSun City, Arizona, United States
ATP Clinical ResearchCosta Mesa, California, United States
Margolin Brain InstituteFresno, California, United States
Investigative siteDenver, Colorado, United States
Berma Research GroupHialeah, Florida, United States
Sunrise Clinical ResearchHollywood, Florida, United States
Center for Clinical TrialsVenice, Florida, United States
Premiere Research Institute @ Palm Beach NeurologyWest Palm Beach, Florida, United States
Medical Associates of North GeorgiaCanton, Georgia, United States
Medical Associates of North GeorgiaCumming, Georgia, United States
Witham Health ServicesLebanon, Indiana, United States
Investigative sitePittsfield, Massachusetts, United States
Rochester Center For Behavioral MedicineRochester Hills, Michigan, United States
Alzheimer's Research CorporationManchester, New Hampshire, United States
Investigative siteLong Branch, New Jersey, United States
Neurobehavioral Research, IncCedarhurst, New York, United States
Eastside Comprehensive Medical CenterNew York, New York, United States
Investigative siteCenterville, Ohio, United States
The Ohio State UniversityColumbus, Ohio, United States
Investigative siteEugene, Oregon, United States
The Clinical Trial CenterJenkintown, Pennsylvania, United States
Senior Adults Specialty ResearchAustin, Texas, United States
Investigative siteBennington, Vermont, United States